Regulatory Insights: Conditional Reimbursement & Drug Registration Updates
Welcome to Carver's regulatory updates podcast for the week of March 29, 2026.
Starting with the European Union, the Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending marketing authorisation for Joenja, an immunostimulant targeting activated phosphoinositide 3-kinase delta syndrome, or APDS. This treatment is intended for patients aged 12 years and older who weigh 45 kilograms or more. The marketing authorisation is granted under exceptional circumstances with specific obligations subject to annual review. Treatment initiation must be conducted by physicians experienced in primary immune deficiencies. Detailed product characteristics, or SmPC, will be published following European Commission authorisation.
In related European Union medical device news, the mandatory use of EUDAMED modules will begin on May 28, 2026. These modules include Actor registration, Unique Device Identification and Device Registration, Notified Bodies and Certificates, and Market Surveillance. Relevant economic operators must complete registration in the Actor module before May 28, 2026. Medical devices regulated under the Medical Device Regulation and In Vitro Diagnostic Regulation placed on the market on or after May 28, 2026, must be registered using the UDI/Device module prior to first market placement. Legacy devices placed before May 28, 2026, must be registered by November 28, 2026.
Also in the European Union, a joint meeting of the Pharmaceutical Committee and the Health Care Professionals’ Working Party took place on March 27, 2026. The meeting provided updates and discussions on pharmaceutical legislation implementation and the European Health Data Space. Key focus areas included engagement with young patients, consumers, and healthcare professionals, implementation updates on revised pharmaceutical legislation, and monitoring vaccine confidence initiatives.
Moving to Nigeria, the National Agency for Food and Drug Administration and Control has introduced revised guidelines for risk categorization of product dossiers for the registration of drug products for human use in 2024. The guidelines establish three risk categories: low, medium, and high, each with specific eligibility criteria and assessment pathways. A notable policy is the 5 plus 5 approach for technology transfer and local manufacturing. All drug product dossiers must be submitted regardless of risk category. Low-risk applications require evidence of prior registration and market presence for at least five years. Medium risk includes injectables, sterile products, narcotics, and products without technology transfer agreements.
In the United States, the Department of Justice announced two case updates from Florida. First, a Gainesville man pleaded guilty to unlawful possession of a homemade silencer and related firearms offenses in federal court. This case highlights ongoing federal enforcement efforts under Operation Take Back America to reduce violent crime and illegal firearms possession. Second, a convicted felon pleaded guilty to unlawful possession of ammunition, reinforcing prosecution efforts against prohibited persons possessing firearms or ammunition. Both cases underscore continued collaboration between federal and local law enforcement agencies.
In Denmark, Buccolam 2.5 milligrams will receive general conditional reimbursement starting April 13, 2026. The reimbursement applies to treatment of prolonged acute convulsive seizures in infants aged six to twelve months. Prescriptions for infants aged three to six months remain hospital-restricted and require monitoring.
In the Czech Republic, updated prices, maximum manufacturer prices, reimbursement amounts, and co-payment limits for categorized and non-categorized prescription-only medicines, or PZLÚ, will take effect on April 1, 2026. These updates reflect the 12 percent value-added tax rate and the Ministry of Health's price regulation dated October 24, 2025. Stakeholders must adhere to updated manufacturer prices and reimbursement levels, apply the 12 percent VAT rate, and comply with conditions and limits for co-payments and reimbursement groups as published.
Finally, in the United States, the Federal Energy Regulatory Commission, or FERC, has clarified filing requirements for Form No. 6, the annual report, and Form No. 6-Q, the quarterly report, for oil pipeline carriers. Filings must include a Corporate Officer Certification submitted electronically. Carriers with annual jurisdictional operating revenues of $500,000 or more must file both forms annually and quarterly, respectively. Carriers with revenues between $350,000 and $500,000 must file specific pages 301 and 700 of Form No. 6 plus page 1. Those with revenues of $350,000 or less must file page 700 plus page 1 of Form No. 6. The annual Form No. 6 is due by April 18 following the calendar year end, and the quarterly Form No. 6-Q is due within 70 days after quarter end.
That wraps up today's regulatory updates. Visit carveragents.ai for more information.
